Last reviewed · How we verify
Seretide™ Accuhaler™
At a glance
| Generic name | Seretide™ Accuhaler™ |
|---|---|
| Also known as | FP, SAL |
| Sponsor | Mylan Pharma UK Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs (PHASE1)
- A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seretide™ Accuhaler™ CI brief — competitive landscape report
- Seretide™ Accuhaler™ updates RSS · CI watch RSS
- Mylan Pharma UK Ltd. portfolio CI